ketanserin has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kats, S | 1 |
| Schönberger, JP | 1 |
| Brands, R | 1 |
| Seinen, W | 1 |
| van Oeveren, W | 1 |
1 review available for ketanserin and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Anti-Infective Agents; Antibodies; Cardiopulmonary By | 2011 |